The incidence of anal intraepithelial neoplasia is rising, particularly among high-risk groups like MSM (men who have sex with men), HIV-positive individuals, and the immunosuppressed.
The progression to invasive anal cancer from high-grade lesions is about 5%, but higher for high-risk patients, and while anal cytology is used for screening, it doesn’t reliably connect to actual disease presence.
Treatment options range from nonoperative methods like topical medications to surgical procedures, but there are still high recurrence rates, emphasizing the need for vigilant surveillance, with no established optimal follow-up guidelines.